Stay updated on Expanded Access to Upadacitinib Clinical Trial
Sign up to get notified when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.

Latest updates to the Expanded Access to Upadacitinib Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.2%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about an expanded access program for upadacitinib and its eligibility criteria, while adding references to Crohn Disease and a new version revision.SummaryDifference9%
- Check29 days agoChange DetectedThe page now indicates that a study is available, with updated contact information for the ABBVIE Call Center, and the revision has been updated to v2.14.4. Previous dates and the indication of unavailability have been removed.SummaryDifference3%
- Check59 days agoChange DetectedThe webpage has been updated to reflect new information regarding Crohn disease and its treatment with upadacitinib, replacing previous references to atopic dermatitis and its treatment. Additionally, the update includes new dates and a shift in the form of medication from an oral tablet to an oral solution.SummaryDifference7%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference3%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference3%
Stay in the know with updates to Expanded Access to Upadacitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.